» Articles » PMID: 24589438

The N-myc Oncogene: Maximizing Its Targets, Regulation, and Therapeutic Potential

Overview
Journal Mol Cancer Res
Specialty Cell Biology
Date 2014 Mar 5
PMID 24589438
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

N-myc (MYCN), a member of the Myc family of basic-helix-loop-helix-zipper (bHLHZ) transcription factors, is a central regulator of many vital cellular processes. As such, N-myc is well recognized for its classic oncogenic activity and association with human neuroblastoma. Amplification and overexpression of N-myc has been described in other tumor types, particularly those of neural origin and neuroendocrine tumors. This review outlines N-myc's contribution to normal development and oncogenic progression. In addition, it highlights relevant transcriptional targets and mechanisms of regulation. Finally, the clinical implications of N-Myc as a biomarker and potential as a target using novel therapeutic approaches are discussed.

Citing Articles

The polyamine transporter ATP13A3 mediates difluoromethylornithine-induced polyamine uptake in neuroblastoma.

Azfar M, Gao W, Van den Haute C, Xiao L, Karsa M, Pandher R Mol Oncol. 2025; 19(3):913-936.

PMID: 39981745 PMC: 11887671. DOI: 10.1002/1878-0261.13789.


Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?.

Wang W, Du Y, Datta S, Fowler J, Sang H, Albadari N Genes Dis. 2025; 12(2):101156.

PMID: 39802403 PMC: 11719324. DOI: 10.1016/j.gendis.2023.101156.


Ependymal Tumors: Overview of the Recent World Health Organization Histopathologic and Genetic Updates with an Imaging Characteristic.

Soni N, Ora M, Bathla G, Desai A, Gupta V, Agarwal A AJNR Am J Neuroradiol. 2024; 45(11):1624-1634.

PMID: 38844368 PMC: 11543070. DOI: 10.3174/ajnr.A8237.


N-MYC impairs innate immune signaling in high-grade serous ovarian carcinoma.

Miranda A, Pattnaik S, Hamilton P, Fuss M, Kalaria S, Laumont C Sci Adv. 2024; 10(20):eadj5428.

PMID: 38748789 PMC: 11095474. DOI: 10.1126/sciadv.adj5428.


Pediatric CNS tumors and 2021 WHO classification: what do oncologists need from pathologists?.

dAmati A, Bargiacchi L, Rossi S, Carai A, Bertero L, Barresi V Front Mol Neurosci. 2024; 17:1268038.

PMID: 38544524 PMC: 10966132. DOI: 10.3389/fnmol.2024.1268038.